+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

United States Epilepsy Drugs Market - Therapeutic Landscape & Forecast 2026-2034

  • PDF Icon

    Report

  • 200 Pages
  • September 2026
  • Region: United States
  • Renub Research
  • ID: 6101927

Research Methodology of United State Epilepsy Drugs Market

The United States Epilepsy Drugs Market had been estimated using a combination of bottom-up and top-down market-sizing approaches, supported by secondary research, patient analysis, prescription-volume assessment, drug pricing analysis, company-level research, and data triangulation. The methodology had been designed to estimate revenues generated from prescription medicines used for the treatment and management of epilepsy across major drug classes, distribution channels, and patient groups in the United States.

1. Market Definition and Scope

  • The market definition had first been established to determine the scope of the United States Epilepsy Drugs Market.
  • The market had included prescription medicines indicated for:
  • Treatment of epilepsy
  • Management of epilepsy
  • Treatment of seizure disorders
  • The assessment had covered major antiseizure medicines across branded and generic categories.

2. Bottom-Up Approach

  • The bottom-up approach had formed the core of the market estimation.
  • The market had been constructed by estimating sales for individual epilepsy drugs and aggregating them.
  • For each drug, the analysis had considered:
  • Prescription volume
  • Number of treated patients
  • Treatment duration
  • Average daily dose
  • Pack size
  • Average selling price
  • Branded versus generic utilization
  • Reimbursement coverage
  • Distribution channel
  • Revenue attributable to epilepsy
  • The calculation had followed: Drug Market Revenue = Prescription/Unit Volume × Net Realized Price
  • Revenues from individual medicines had then been aggregated to determine the overall U.S. epilepsy drugs market.

3. Patient-Based Estimation

  • A separate patient-based model had been used to validate the bottom-up calculation.
  • The analysis had estimated:
  • Population diagnosed with epilepsy
  • Patients experiencing recurrent seizures
  • Patients requiring pharmacological treatment
  • Patients receiving antiseizure medications
  • The calculation had followed: Total Epilepsy Patient Pool × Treatment Rate × Average Annual Drug Cost = Estimated Market Value
  • The patient population had been further assessed by:
  • Newly diagnosed patients
  • Established patients
  • Refractory epilepsy patients
  • Pediatric patients
  • Adult patients
  • This approach had helped establish the relationship between the treated population and pharmaceutical spending.

4. Prescription Volume Analysis

  • Prescription activity had been analyzed to determine actual utilization of epilepsy medicines.
  • The analysis had considered:
  • New prescriptions
  • Total prescriptions
  • Refills
  • Chronic treatment patterns
  • Monotherapy
  • Adjunctive therapy
  • Switching between drugs
  • Generic substitution
  • Since epilepsy treatment had often involved long-term medication use, refill activity had been an important indicator of annual drug consumption.
  • Prescription trends had also been compared with patient prevalence and incidence estimates to identify inconsistencies in the market model.

5. Top-Down Approach

  • A top-down methodology had been used as an independent validation of the bottom-up estimate.
  • The analysis had started with broader pharmaceutical markets, including:
  • U.S. neurological pharmaceuticals
  • Central nervous system therapeutics
  • The share attributable to epilepsy treatment had then been estimated using:
  • Therapeutic-class composition
  • Prescription data
  • Product revenues
  • Industry information
  • The calculation had followed: Relevant U.S. Pharmaceutical Market × Epilepsy Drug Share = Estimated Epilepsy Drugs Market
  • The resulting estimate had been compared with product-level and patient-level calculations.
  • The top-down approach had therefore served primarily as a cross-check rather than the sole market-sizing method.

6. Drug-Class Analysis

  • The market had been estimated separately by therapeutic drug class.
  • Traditional antiseizure medicines had been assessed alongside newer-generation therapies.
  • Drug-class adoption had been evaluated based on:
  • Approved indications
  • Treatment guidelines
  • Patient response
  • Safety considerations
  • Physician prescribing patterns
  • For each drug class, the calculation had followed: Drug Class → Number of Patients/Prescriptions → Average Treatment Cost → Annual Revenue
  • Individual drug-class revenues had then been aggregated to determine the total market.

7. Branded and Generic Drug Analysis

  • The U.S. epilepsy drugs market had been divided into:
  • Branded medicines
  • Generic medicines
  • Branded drugs had been evaluated using:
  • Manufacturer revenues
  • Prescription volumes
  • List prices
  • Estimated discounts
  • Payer rebates, where available
  • Generic medicines had been estimated using:
  • Prescription volumes
  • Average generic prices
  • This distinction had been important because generic substitution could reduce average revenue per prescription even when prescription volumes remained high.
  • Branded pricing had therefore not been uniformly applied to all prescriptions.

8. Average Selling Price Analysis

  • Drug pricing had been assessed at the individual product level.
  • The analysis had considered:
  • Wholesale acquisition price
  • Average wholesale price
  • Generic pricing
  • Brand pricing
  • Dosage strength
  • Pack size
  • Formulation
  • Distribution discounts
  • Rebates
  • Patient assistance programs
  • Payer negotiations
  • Where only list-price information had been available, adjustments had been made to estimate net realized pharmaceutical revenue.
  • Average annual treatment costs had then been calculated for major epilepsy medicines.

9. Epilepsy-Indication Revenue Adjustment

  • Several antiseizure medicines had been prescribed for multiple neurological or psychiatric indications.
  • Total product revenue had therefore not automatically been treated as epilepsy-drug revenue.
  • The epilepsy-attributable share had been estimated using:
  • Approved indications
  • Prescription data
  • Physician interviews
  • Therapeutic utilization patterns
  • Published clinical literature
  • Company disclosures
  • The calculation had followed: Total Product Revenue × Epilepsy Indication Share = Epilepsy-Attributed Revenue
  • This adjustment had helped minimize potential market overestimation.

10. Distribution Channel Analysis

  • The market had been assessed across major pharmaceutical distribution channels:
  • Hospital pharmacies
  • Drug stores and retail pharmacies
  • Online providers
  • The analysis had evaluated differences in:
  • Pricing
  • Prescription volumes
  • Reimbursement
  • Purchasing behavior
  • Channel-level assessment had helped determine the contribution of different distribution pathways to total market revenue.

11. Company-Level Analysis

  • Major pharmaceutical companies involved in epilepsy drug development and commercialization had been identified.
  • The analysis had considered:
  • Epilepsy drug portfolios
  • Product revenues
  • Prescription trends
  • New drug launches
  • Regulatory approvals
  • Clinical development pipelines
  • Generic competition
  • Market-access strategies
  • Partnerships and licensing agreements
  • Company-level revenue information had been used to validate the product-level market calculation.
  • Total company revenue had not been directly counted as epilepsy-drug revenue because pharmaceutical companies had operated across multiple therapeutic areas.

12. New Drug Launches and Regulatory Approvals

  • Historical and forecast estimates had incorporated new epilepsy-drug launches and regulatory developments.
  • The analysis had assessed the impact of:
  • FDA approvals
  • New indications
  • Extended-release formulations
  • Novel mechanisms of action
  • Pediatric approvals
  • Combination therapies
  • Generic launches
  • Patent expirations
  • New branded therapies had potentially increased market revenue through premium pricing.
  • Generic launches had potentially reduced average selling prices and shifted revenue toward lower-cost alternatives.

13. Patent Expiration and Generic Competition

  • Patent expiration had been incorporated into the forecast because it could significantly affect market revenues.
  • For major branded products approaching loss of exclusivity, the model had assessed: Patent Expiration → Generic Entry → Price Reduction → Brand Share Decline → Market Revenue Impact
  • Generic penetration assumptions had been developed using:
  • Historical substitution patterns
  • Comparable pharmaceutical products
  • Product-level market behavior
  • This analysis had helped distinguish prescription-volume growth from revenue growth.

14. Secondary Research

  • Extensive secondary research had been conducted to develop the initial market model.
  • Sources had included:
  • U.S. government healthcare databases
  • FDA publications
  • CDC information
  • NIH and clinical research sources
  • CMS data
  • Pharmaceutical company annual reports
  • Investor presentations
  • Drug-label information
  • Prescription databases
  • Pharmaceutical industry publications
  • Clinical guidelines
  • Medical associations
  • Publicly available pricing information
  • Secondary information had been used to develop assumptions relating to:
  • Patient population
  • Drug utilization
  • Pricing
  • Treatment patterns
  • Competitive dynamics

15. Market Forecast

  • After establishing the historical base year, the forecast had been developed using product-, drug-class-, and patient-specific assumptions.
  • The forecast had considered:
  • Growth in diagnosed epilepsy patients
  • Treatment rates
  • Prescription volumes
  • New drug launches
  • Generic penetration
  • Patent expirations
  • Pricing changes
  • New indications
  • Adoption of newer therapies
  • Changes in reimbursement
  • Treatment patterns
  • Individual products and drug classes had been assigned different growth assumptions instead of applying one growth rate to the entire market.
  • The forecast had followed: Future Market Size = Base-Year Market Size × (1 + CAGR)ⁿ
  • n had represented the number of years in the forecast period.

16. Data Triangulation

  • The final market size had been established by comparing multiple independent estimation approaches.
  • Demand-Side Approach: Treated patients × Prescriptions/Treatment Duration × Average Realized Price
  • Supply-Side Approach: Product sales + Estimated generic sales + Relevant distribution revenue adjustments.
  • Top-Down Approach: U.S. Neurological Pharmaceutical Market × Epilepsy-Related Share
  • The results had been compared with:
  • Prescription data
  • Company disclosures
  • Pricing information
  • Epidemiological statistics
  • Significant differences had been investigated, and underlying assumptions had been revised where necessary.

17. Third-Party Validation

  • Preliminary market estimates and key assumptions had been subjected to third-party validation.
  • Independent healthcare and pharmaceutical industry participants had been consulted to review selected findings relating to:
  • Patient treatment rates
  • Drug-class utilization
  • Brand/generic mix
  • Pricing
  • Prescription trends
  • Market segmentation
  • Competitive developments
  • Forecast assumptions
  • Third-party feedback had been used as an additional validation layer to determine whether the estimated market structure and growth assumptions were consistent with industry practices.

18. Final Market Size Determination

  • The final United States Epilepsy Drugs Market size had been established after completing:
  • Bottom-up market estimation
  • Patient-based analysis
  • Prescription-volume analysis
  • Drug pricing assessment
  • Drug-class analysis
  • Brand and generic assessment
  • Company-level research
  • Top-down validation
  • Secondary research
  • Third-party validation
  • Data triangulation
  • The final estimate had been reconciled across patient demand, prescription utilization, drug pricing, product revenues, and broader pharmaceutical market indicators to establish a consistent market value.

United States Epilepsy Drugs Market Size and Forecast 2026-2034

United States Epilepsy Drugs Market is expected to reach US$ 5.29 Billion by 2034 from US$ 3.62 Billion in 2025, with a CAGR of 4.31% from 2026 to 2034. The United States epilepsy drugs market is driven by rising epilepsy prevalence, increasing diagnosis rates, continuous innovation in anti-seizure medications, growing adoption of precision therapies, and strong investments in neurological research. Regulatory support and expanding access to advanced treatments further accelerate market growth.

United States Epilepsy Drugs Industry Overview

Epilepsy drugs, also known as anti-epileptic drugs (AEDs) or anti-seizure medications (ASMs), are pharmaceutical therapies used to control and prevent recurrent seizures caused by abnormal electrical activity in the brain. These medications work through different mechanisms, including modulation of sodium channels, calcium channels, gamma-aminobutyric acid (GABA) activity, and glutamate signaling. Commonly prescribed drugs include levetiracetam, lamotrigine, valproate, and topiramate. While many patients achieve seizure control with medication, some experience drug-resistant epilepsy requiring advanced therapies. Continuous research is leading to safer and more effective treatments with improved tolerability and fewer neurological side effects.

The U.S. epilepsy drugs market is experiencing steady expansion due to the growing burden of epilepsy and increasing demand for effective seizure management therapies. Ongoing pharmaceutical innovation has introduced newer-generation anti-seizure medications with improved safety and efficacy profiles. Increased awareness campaigns, better diagnostic capabilities, and improved healthcare access are supporting earlier treatment initiation. Additionally, strong investment in neurological drug development and a robust pipeline of novel therapies for drug-resistant epilepsy continue to strengthen market prospects and create long-term growth opportunities.

Recent Developments in United States Epilepsy Drugs Market

  • April 2025: The U.S. FDA approved an expanded indication for Valtoco (diazepam nasal spray), allowing its use in children aged 2 to 5 years for the acute treatment of seizure clusters. The label expansion increased access to rescue therapy among younger pediatric epilepsy patients and broadened the product’s market reach.
  • April 2025: Neurelis secured FDA approval for Valtoco (diazepam nasal spray) as a short-term rescue treatment for seizure clusters in patients aged two years and older. The product's orphan drug exclusivity and favorable clinical profile reinforced its role in emergency seizure management and strengthened the company's presence in the U.S. epilepsy therapeutics market.
  • January 2025: SK Biopharmaceuticals partnered with Eurofarma to introduce a telemedicine-focused initiative in the United States aimed at improving epilepsy care. The collaboration seeks to enhance patient access to specialized neurological support, treatment monitoring, and disease management services through digital healthcare solutions.

Growth Drivers for the United States Epilepsy Drugs Market

Rising Prevalence of Epilepsy and Expanding Patient Population

The increasing prevalence of epilepsy remains the primary growth driver for the U.S. epilepsy drugs market. The CDC estimates that approximately 2.9 million adults in the United States are living with active epilepsy, representing around 1% of the adult population. Growing incidence among aging populations, traumatic brain injury survivors, stroke patients, and individuals with neurological disorders is expanding the addressable patient base. As diagnosis rates improve through enhanced neurological screening and public awareness programs, more patients are entering long-term pharmacological treatment pathways.

The growing burden of epilepsy also increases demand for newer anti-seizure medications that offer improved seizure control with fewer adverse effects. Healthcare providers are increasingly adopting individualized treatment strategies, creating opportunities for premium and targeted therapies.

In November 2025, Axsome Therapeutics announced the acquisition of AZD7325, a novel subtype-selective GABAA receptor modulator being developed for epilepsy treatment, strengthening the innovation pipeline in the epilepsy market.

Advancements in Novel Drug Development and Precision Therapies

Continuous innovation in anti-seizure therapeutics is significantly boosting market growth. Pharmaceutical companies are developing next-generation therapies that target specific seizure mechanisms while minimizing cognitive and behavioral side effects associated with older medications. Research efforts increasingly focus on precision medicine, genetic epilepsies, and treatment-resistant epilepsy populations that have historically lacked effective options.

Emerging therapies include gene-based medicines, cell therapies, receptor-specific modulators, and novel neurotransmitter-targeting drugs. These innovations improve clinical outcomes and support premium pricing opportunities. The strong clinical pipeline is expected to transform epilepsy treatment over the next decade.

In February 2025, Stoke Therapeutics and Biogen advanced development of zorevunersen for Dravet syndrome, a severe childhood epilepsy, with plans for a global Phase III program. The collaboration highlights growing investment in precision therapies for epilepsy.

Increasing Focus on Drug-Resistant Epilepsy Treatment

Approximately one-third of epilepsy patients continue to experience seizures despite available medications, creating significant unmet clinical needs. This has encouraged extensive investment in therapies targeting drug-resistant epilepsy. Pharmaceutical companies and biotechnology firms are accelerating development of innovative treatments capable of addressing refractory seizure disorders.

Growing recognition of treatment-resistant epilepsy among physicians and payers is also increasing reimbursement support for advanced therapies. Furthermore, improved clinical trial infrastructure and regulatory incentives are encouraging the development of breakthrough neurological medicines.

In May 2024, Supernus Pharmaceuticals reported positive interim Phase IIa results for SPN-817, a novel first-in-class therapy being investigated for treatment-resistant seizures, demonstrating continued innovation in difficult-to-treat epilepsy populations.

Challenges in the United States Epilepsy Drugs Market

High Prevalence of Drug-Resistant Epilepsy

Despite significant advances in anti-seizure medications, a substantial proportion of patients continue to experience uncontrolled seizures. Drug-resistant epilepsy remains one of the biggest challenges facing the market because existing therapies often fail to achieve complete seizure freedom. Patients frequently require multiple medications, increasing treatment complexity, adverse effects, and healthcare costs. Persistent seizure activity can also lead to reduced quality of life, cognitive impairment, and increased hospitalization rates. These limitations create pressure on manufacturers to develop more effective therapies while demonstrating superior clinical outcomes and long-term safety compared with established treatments.

Safety Concerns and Treatment Adherence Issues

Long-term use of anti-seizure medications may be associated with adverse effects such as dizziness, fatigue, mood changes, memory impairment, and weight fluctuations. These side effects often reduce treatment adherence, particularly among pediatric and elderly patients. Non-compliance can result in breakthrough seizures and increased healthcare utilization. In addition, many epilepsy patients suffer from multiple coexisting conditions requiring complex medication regimens, raising the risk of drug interactions. Pharmaceutical companies must therefore balance efficacy with tolerability while meeting increasingly stringent regulatory and post-marketing safety requirements, which can lengthen development timelines and increase costs.

California Epilepsy Drugs Market

California represents the largest epilepsy drugs market in the United States due to its large population, advanced healthcare infrastructure, and strong concentration of neurological specialty centers. The state benefits from extensive access to epilepsy diagnosis, treatment, and clinical research programs. Growing awareness of neurological disorders and increasing adoption of innovative therapies continue to support demand for anti-seizure medications. California is also home to numerous biotechnology companies developing advanced epilepsy treatments, strengthening regional innovation.

According to CDC estimates, approximately 1% of U.S. adults live with active epilepsy. Applying this prevalence to California’s adult population indicates several hundred thousand residents potentially require ongoing epilepsy treatment, supporting substantial pharmaceutical demand.

Texas Epilepsy Drugs Market

Texas is a key contributor to the U.S. epilepsy drugs market due to its large population, expanding healthcare infrastructure, and increasing access to neurological specialty services. Demand for anti-seizure medications is growing as awareness of epilepsy improves and more patients receive timely diagnosis and treatment. Major metropolitan areas such as Houston, Dallas, and San Antonio host leading medical centers and epilepsy programs that support the adoption of advanced therapies. The state also benefits from ongoing investments in healthcare delivery and neurological research, which enhance access to innovative treatment options. As the burden of neurological disorders continues to rise, pharmaceutical companies are increasingly focusing on Texas as an important market for epilepsy therapeutics.

According to the Texas Department of State Health Services, epilepsy affects an estimated more than 250,000 Texans, making it one of the most common serious neurological disorders in the state and creating substantial demand for anti-seizure medications and long-term disease management services.

Florida Epilepsy Drugs Market

Florida's epilepsy drugs market is supported by the state's large elderly population, increasing prevalence of neurological disorders, and expanding access to specialty epilepsy care. Demand for anti-seizure medications continues to rise as healthcare providers focus on long-term seizure management and improved patient outcomes. The presence of specialized epilepsy centers, academic hospitals, and community support programs further strengthens treatment accessibility across the state. Growing awareness initiatives and advancements in diagnostic technologies are also contributing to earlier diagnosis and increased utilization of pharmaceutical therapies. In addition, Florida's healthcare system is actively involved in supporting patients through medication assistance and epilepsy management programs, creating favorable conditions for sustained market growth.

According to the Florida Department of Health, an estimated 172,600 individuals in Florida were living with active epilepsy in 2023, including approximately 146,400 adults and 26,200 children, highlighting the substantial treatment population within the state.

New York Epilepsy Drugs Market

New York remains a key market for epilepsy drugs due to its advanced healthcare ecosystem, strong neurological research infrastructure, and high concentration of specialty treatment centers. The state continues to play an important role in epilepsy clinical trials and adoption of innovative therapies for both adult and pediatric populations. Growing interest in precision medicine and improved access to specialty neurological care are expected to support sustained pharmaceutical demand. New York also benefits from strong public health initiatives focused on neurological disease awareness and management.

The New York State Department of Health estimates that approximately 215,000 New Yorkers are living with active epilepsy, and nearly 9,000 new cases are diagnosed annually. This substantial patient population supports consistent demand for anti-seizure medications and advanced epilepsy treatments across the state.

United States First-Generation Drugs Market

The first-generation anti-epileptic drugs segment continues to maintain a significant presence in the U.S. epilepsy drugs market due to its long history of clinical use and proven effectiveness in seizure control. Drugs such as phenytoin, carbamazepine, valproic acid, and phenobarbital remain widely prescribed across healthcare settings for the management of various seizure types. Their broad availability in generic formulations makes them a cost-effective treatment option, particularly for patients requiring long-term therapy. Although newer-generation anti-seizure medications offer improved safety and tolerability, first-generation drugs continue to be utilized because of established physician confidence, extensive clinical evidence, and affordability. These factors ensure sustained demand despite ongoing therapeutic innovation.

United States Focal Seizures Market

The focal seizures segment represents a major component of the U.S. epilepsy drugs market because focal-onset seizures are among the most commonly diagnosed forms of epilepsy. These seizures originate in a specific region of the brain and often require long-term pharmacological management. Growing awareness, improved diagnostic technologies, and increasing access to neurological care are contributing to earlier identification and treatment of focal epilepsy. Pharmaceutical companies are actively developing therapies specifically designed to improve seizure control in focal seizure patients while minimizing adverse effects. The segment also benefits from increasing adoption of personalized treatment approaches and newer anti-seizure medications. As the prevalence of focal epilepsy remains substantial, demand for effective therapeutic options is expected to continue expanding.

United States Hospital Pharmacies Market

Hospital pharmacies constitute an important distribution channel within the U.S. epilepsy drugs market, particularly for patients requiring specialized neurological care and complex treatment regimens. These pharmacies facilitate access to a wide range of anti-seizure medications, including newly approved therapies and treatments for drug-resistant epilepsy. Hospitals play a central role in managing acute seizure episodes, initiating therapy after diagnosis, and optimizing medication regimens for patients with difficult-to-control epilepsy. The growing emphasis on multidisciplinary epilepsy care has further increased the importance of hospital-based pharmaceutical services. In addition, rising hospitalization rates associated with severe seizures and neurological complications continue to support demand through this channel, making hospital pharmacies a critical contributor to overall market growth.

Market Segmentations

Drugs Category

  • First Generation Drugs
  • Second Generation Drugs
  • Third Generation Drugs

Seizure Types

  • Focal Seizures
  • Generalized Seizures
  • Non-Epileptic Seizures

Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

States

  • California
  • Texas
  • New York
  • Florida
  • Illinois
  • Pennsylvania
  • Ohio
  • Georgia
  • New Jersey
  • Washington
  • North Carolina
  • Massachusetts
  • Virginia
  • Michigan
  • Maryland
  • Colorado
  • Tennessee
  • Indiana
  • Arizona
  • Minnesota
  • Wisconsin
  • Missouri
  • Connecticut
  • South Carolina
  • Oregon
  • Louisiana
  • Alabama
  • Kentucky
  • Rest of United States

All the Key players have been covered with 5 Viewpoints

  • Overviews
  • Key Person
  • Recent Developments
  • SWOT Analysis
  • Revenue Analysis

Key Players Analysis

  • Eisai Co., Ltd.
  • UCB Inc.
  • H. Lundbeck A/S
  • GW Pharmaceuticals Plc.
  • Abbott Laboratories
  • Alkem Laboratories Limited
  • Bausch Health Companies Inc.
  • GSK plc.

Table of Contents

1. Introduction
2. Research & Methodology
2.1 Data Source
2.1.1 Primary Sources
2.1.2 Secondary Sources
2.2 Research Approach
2.2.1 Top-Down Approach
2.2.2 Bottom-Up Approach
2.3 Forecast Projection Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Exploring the Disease - Background and Key Insights
5.1 Introduction
5.2 Causes
5.3 Classificationof Epilepsies
5.3.1 West Syndrome
5.3.2 Dravet syndrome
5.3.3 Lennox-Gastaut syndrome
5.3.4 Landau-Kleffner syndrome
5.3.5 Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS)
5.3.6 CDKL5 deficiency disorder (CDD)
5.4 Risk Factors
5.5 Pathophysiology
5.6 Diagnosis
5.6.1 Diagnostic Guidelines
5.6.1.1 NICE: Epilepsies in Children, Young People, and Adults (2022)
5.6.1.2 American Family Physician: Diagnostic Evaluation (2017)
5.6.1.3 The French National Authority for Health (HAS): 2020
5.6.1.4 German Society for Neurology (DGN) Guidelines: Diagnostics and Therapy in Neurology (2023)
5.7 Treatment
5.7.1 Antiepileptic Medications (AEDs)
5.7.2 Receptor Blockers
5.7.3 Others
5.7.4 Diet Therapy
5.7.5 Surgery
5.7.5.1 Phase I Evaluation (Noninvasive Tests)
5.7.5.2 Phase II Evaluation (Invasive Mon)
5.7.6 Treatment Algorithm for Medical Condition
5.7.7 Treatment Guidelines
5.7.7.1 American Epilepsy Society
5.7.7.2 American Family Physician - Epilepsy Treatment Options (2017)
5.7.7.3 The International League against Epilepsy (ILAE) Epilepsy Guidelines
5.7.7.4 NICE Guidelines: (2022)
5.7.8 Living and Coping with Epilepsy
6. United States Epilepsy Drugs Market
6.1 Historical Market Trends
6.2 Market Forecast
7. Market Share Analysis
7.1 By Drugs Category
7.2 By Seizure Type
7.3 By Distribution Channel
7.4 By States
8. Drugs Category - Historical and Current Market Trends & Forecast
8.1 First Generation Drugs
8.2 Second Generation Drugs
8.3 Third Generation Drugs
9. Seizure Types - Historical and Current Market Trends & Forecast
9.1 Focal Seizures
9.2 Generalized Seizures
9.3 Non-Epileptic Seizures
10. Distribution Channels - Historical and Current Market Trends & Forecast
10.1 Hospital Pharmacies
10.2 Drug Stores and Retail Pharmacies
10.3 Online Providers
11. States - Historical and Current Market Trends & Forecast
11.1 California
11.2 Texas
11.3 New York
11.4 Florida
11.5 Illinois
11.6 Pennsylvania
11.7 Ohio
11.8 Georgia
11.9 New Jersey
11.10 Washington
11.11 North Carolina
11.12 Massachusetts
11.13 Virginia
11.14 Michigan
11.15 Maryland
11.16 Colorado
11.17 Tennessee
11.18 Indiana
11.19 Arizona
11.20 Minnesota
11.21 Wisconsin
11.22 Missouri
11.23 Connecticut
11.24 South Carolina
11.25 Oregon
11.26 Louisiana
11.27 Alabama
11.28 Kentucky
11.29 Rest of the United States
12. Porter’s Five Forces Analysis
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Rivalry
12.4 Threat of New Entrants
12.5 Threat of Substitutes
13. SWOT Analysis
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threat
14. Analysis of Marketed Medications/Drugs
14.1 Key Players
14.2 EPIDIOLEX/EPIDYOLEX (cannabidiol) - Jazz Pharmaceuticals
14.2.1 Description of Drugs
14.2.2 Regulatory Milestones
14.2.3 Clinical Development Process
14.2.4 Safety and Efficacy
14.3 XCOPRI/ONTOZRY(cenobamate) - SK Biopharmaceutical/ Pharma/Ono Pharmaceutical
14.3.1 Description of Drugs
14.3.2 Regulatory Milestones
14.3.3 Clinical Development Process
14.3.4 Safety and Efficacy
14.4 FINTEPLA (fenfluramine) - UCB/Nippon Shinyaku
14.4.1 Description of Drugs
14.4.2 Regulatory Milestones
14.4.3 Clinical Development Process
14.4.4 Safety and Efficacy
14.5 NAYZILAM (midazolam) nasal spray - UCB Pharma
14.5.1 Description of Drugs
14.5.2 Regulatory Milestones
14.5.3 Clinical Development Process
14.5.4 Safety and Efficacy
14.6 VALTOCO (diazepam nasal spray) - Neurelis/Aculys Pharma
14.6.1 Description of Drugs
14.6.2 Regulatory Milestones
14.6.3 Clinical Development Process
14.6.4 Safety and Efficacy
14.7 ZTALMY (ganaxolone) - Marinus Pharmaceuticals/Ovid Therapeutics/Orion
14.7.1 Description of Drugs
14.7.2 Regulatory Milestones
14.7.3 Clinical Development Process
14.7.4 Safety and Efficacy
14.8 BRIVIACT/NUBRIVEO (brivaracetam) - UCB Pharma
14.8.1 Description of Drugs
14.8.2 Regulatory Milestones
14.8.3 Clinical Development Process
14.8.4 Safety and Efficacy
14.9 FYCOMPA (perampanel) - Eisai/Catalyst Pharmaceutical
14.9.1 Description of Drugs
14.9.2 Regulatory Milestones
14.9.3 Clinical Development Process
14.9.4 Safety and Efficacy
14.10 OXTELLAR XR (oxcarbazepine) - Supernus Pharmaceuticals
14.10.1 Description of Drugs
14.10.2 Regulatory Milestones
14.10.3 Clinical Development Process
14.10.4 Safety and Efficacy
14.11 VIMPAT (lacosamide) - UCB Pharma/Daiichi Sankyo
14.11.1 Description of Drugs
14.11.2 Regulatory Milestones
14.11.3 Clinical Development Process
14.11.4 Safety and Efficacy
15. Analysis of Emerging Drugs
15.1 Key Cross Competition
15.2 XEN1101 - Xenon Pharmaceuticals
15.2.1 Description of Drug
15.2.2 Clinical Research & Development
15.2.3 Safety and efficacy
15.3 LIBERVANT (diazepam buccal film) - Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)
15.3.1 Description of Drug
15.3.2 Clinical Research & Development
15.3.3 Safety and efficacy
15.4 Soticlestat (TAK-935) - Takeda/Ovid Therapeutics
15.4.1 Description of Drug
15.4.2 Clinical Research & Development
15.4.3 Safety and efficacy
15.5 COMFYDE (carisbamate) - SK Biopharmaceuticals (SK Life Science)
15.5.1 Description of Drug
15.5.2 Clinical Research & Development
15.5.3 Safety and efficacy
15.6 BHV-7000 (KB-3061) - Biohaven Pharmaceuticals/Knopp Biosciences
15.6.1 Description of Drug
15.6.2 Clinical Research & Development
15.6.3 Safety and efficacy
15.7 STACCATO alprazolam (benzodiazepine) - UCB Pharma/Alexza Pharmaceuticals
15.7.1 Description of Drug
15.7.2 Clinical Research & Development
15.7.3 Safety and efficacy
15.8 NBI-827104 (ACT-709478) - Neurocrine Biosciences/Idorsia Pharmaceuticals
15.8.1 Description of Drug
15.8.2 Clinical Research & Development
15.8.3 Safety and efficacy
15.9 Ivermectin (EQU-001) - Equilibre Biopharmaceuticals
15.9.1 Description of Drug
15.9.2 Clinical Research & Development
15.9.3 Safety and efficacy
16. Regulations and Reimbursement Policies
17. Key Players Analysis
17.1 Eisai Co., Ltd.
17.1.1 Overviews
17.1.2 Key Person
17.1.3 Recent Developments
17.1.4 SWOT Analysis
17.1.5 Revenue Analysis
17.2 UCB Inc.
17.2.1 Overviews
17.2.2 Key Person
17.2.3 Recent Developments
17.2.4 SWOT Analysis
17.2.5 Revenue Analysis
17.3 H. Lundbeck A/S
17.3.1 Overviews
17.3.2 Key Person
17.3.3 Recent Developments
17.3.4 SWOT Analysis
17.3.5 Revenue Analysis
17.4 GW Pharmaceuticals Plc.
17.4.1 Overviews
17.4.2 Key Person
17.4.3 Recent Developments
17.4.4 SWOT Analysis
17.4.5 Revenue Analysis
17.5 Abbott Laboratories
17.5.1 Overviews
17.5.2 Key Person
17.5.3 Recent Developments
17.5.4 SWOT Analysis
17.5.5 Revenue Analysis
17.6 Alkem Laboratories Limited
17.6.1 Overviews
17.6.2 Key Person
17.6.3 Recent Developments
17.6.4 SWOT Analysis
17.6.5 Revenue Analysis
17.7 Bausch Health Companies Inc.
17.7.1 Overviews
17.7.2 Key Person
17.7.3 Recent Developments
17.7.4 SWOT Analysis
17.7.5 Revenue Analysis
17.8 GSK plc.
17.8.1 Overviews
17.8.2 Key Person
17.8.3 Recent Developments
17.8.4 SWOT Analysis
17.8.5 Revenue Analysis
17.9 Novartis AG
17.9.1 Overviews
17.9.2 Key Person
17.9.3 Recent Developments
17.9.4 SWOT Analysis
17.9.5 Revenue Analysis
17.10 Pfizer Inc.
17.10.1 Overviews
17.10.2 Key Person
17.10.3 Recent Developments
17.10.4 SWOT Analysis
17.10.5 Revenue Analysis

Companies Mentioned

  • Eisai Co., Ltd.
  • UCB Inc.
  • H. Lundbeck A/S
  • GW Pharmaceuticals Plc.
  • Abbott Laboratories
  • Alkem Laboratories Limited
  • Bausch Health Companies Inc.
  • GSK plc.

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...